Notably, in CD14+ cells collected from the same patients with early stages of HCC after initial treatment, expression levels of both PD-Ls were found to be decreased (PD-L1, 18.7 ± 4.5%; PD-L2, 50.3 ± 35.7%) (Figure 3a). The gene discussed is CD14; the disease is hepatocellular carcinoma.